China National Center for Cardiovascular Diseases — Biomedical Watch V2

Traitements13programmes

Essais5liés

Publications0liées

SourceDBlocale

Traitements

13

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
DopamineComparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring	Insuffisance cardiaque, Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
EpinephrineComparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring	Insuffisance cardiaque, Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
IVUS-Guided Sirolimus-Coated BalloonThe goal of this interventional study is to evaluate the efficacy and safety of an intravascular ultrasound (IVUS)-guided sirolimus-coated balloon (SCB)-based strategy versus planned sirolimus-eluting stent (SES) implantation in patients with acute coronary syndrome (ACS) and de novo large-vessel coronary lesions. The main question is whether the SCB-based strategy is non-inferior to the SES strategy with respect to in-segment late lumen loss (LLL) at 9 months. Following adequate lesion preparation and confirmation according to the prespecified angiographic and IVUS criteria that the target lesion is suitable for both randomized treatment strategies, participants will be randomly assigned to undergo either SCB treatment without routine stent implantation or planned SES implantation. In the SCB group, bail-out SES implantation will be performed when clinically necessary, such as in cases of significant residual stenosis or flow-limiting dissection. Participants will undergo angiographic and IVUS follow-up at 9 months, and clinical outcomes will be assessed through 12 months.	Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
IVUS-Guided Sirolimus-Eluting StentThe goal of this interventional study is to evaluate the efficacy and safety of an intravascular ultrasound (IVUS)-guided sirolimus-coated balloon (SCB)-based strategy versus planned sirolimus-eluting stent (SES) implantation in patients with acute coronary syndrome (ACS) and de novo large-vessel coronary lesions. The main question is whether the SCB-based strategy is non-inferior to the SES strategy with respect to in-segment late lumen loss (LLL) at 9 months. Following adequate lesion preparation and confirmation according to the prespecified angiographic and IVUS criteria that the target lesion is suitable for both randomized treatment strategies, participants will be randomly assigned to undergo either SCB treatment without routine stent implantation or planned SES implantation. In the SCB group, bail-out SES implantation will be performed when clinically necessary, such as in cases of significant residual stenosis or flow-limiting dissection. Participants will undergo angiographic and IVUS follow-up at 9 months, and clinical outcomes will be assessed through 12 months.	Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
Manual Clinical Data ReviewThis study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in classifying coronary syndrome subtypes from admission history of present illness. Participating clinicians will classify a set of cases first without AI assistance and then with assistance from the OCR-LLM framework. The primary outcome is the change in classification accuracy between unaided and AI-assisted assessments.	Maladie coronarienne	À vérifier	À vérifier	China	À vérifier
NorepinephrineThe goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are: Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine? Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest? Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment. Participants will: Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.	Accident vasculaire cérébral, Insuffisance cardiaque, Maladie coronarienne	Non applicable	Ralentissement de la progression	China	À vérifier
OCR-Prompt-LLM Information Extraction and Classification Workflow (OCR-Prompt-LLM)This study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in classifying coronary syndrome subtypes from admission history of present illness. Participating clinicians will classify a set of cases first without AI assistance and then with assistance from the OCR-LLM framework. The primary outcome is the change in classification accuracy between unaided and AI-assisted assessments.	Maladie coronarienne	À vérifier	À vérifier	China	À vérifier
Partial Cardiac DenervationPostoperative atrial fibrillation (POAF) is the most common arrhythmia following cardiac surgery and is associated with increased risks of mortality, stroke, myocardial infarction, and hospital readmission. The cardiac autonomic nervous system plays an important role in the development of POAF and may represent a potential target for preventive intervention. The CALM trial is a multicenter, randomized controlled trial designed to evaluate the efficacy and safety of partial cardiac denervation for the prevention of POAF in patients undergoing isolated coronary artery bypass grafting (CABG). A total of approximately 1,470 participants will be randomly assigned in a 1:1 ratio to undergo CABG with partial cardiac denervation or CABG alone. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad. The trial will evaluate the incidence of POAF within the first 6 postoperative days and the occurrence of long-term adverse clinical events. Participants will undergo scheduled rhythm monitoring and clinical follow-up, and all participants will be followed until the last enrolled participant completes 3 years of follow-up after surgery.	Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
IVUS-Guided Sirolimus-Coated BalloonThe goal of this interventional study is to evaluate the efficacy and safety of an intravascular ultrasound (IVUS)-guided sirolimus-coated balloon (SCB)-based strategy versus planned sirolimus-eluting stent (SES) implantation in patients with acute coronary syndrome (ACS) and de novo large-vessel coronary lesions. The main question is whether the SCB-based strategy is non-inferior to the SES strategy with respect to in-segment late lumen loss (LLL) at 9 months. Following adequate lesion preparation and confirmation according to the prespecified angiographic and IVUS criteria that the target lesion is suitable for both randomized treatment strategies, participants will be randomly assigned to undergo either SCB treatment without routine stent implantation or planned SES implantation. In the SCB group, bail-out SES implantation will be performed when clinically necessary, such as in cases of significant residual stenosis or flow-limiting dissection. Participants will undergo angiographic and IVUS follow-up at 9 months, and clinical outcomes will be assessed through 12 months.	Maladie coronarienne	Non applicable	À vérifier	China	À vérifier
NorepinephrineThe goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are: Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine? Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest? Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment. Participants will: Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.	Maladie coronarienne	Non applicable	Ralentissement de la progression	South Korea	À vérifier
NorepinephrineThe goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are: Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine? Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest? Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment. Participants will: Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.	Maladie coronarienne	Non applicable	Ralentissement de la progression	China	À vérifier
OCR-Prompt-LLM Information Extraction and Classification Workflow (OCR-Prompt-LLM)This study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in classifying coronary syndrome subtypes from admission history of present illness. Participating clinicians will classify a set of cases first without AI assistance and then with assistance from the OCR-LLM framework. The primary outcome is the change in classification accuracy between unaided and AI-assisted assessments.	Maladie coronarienne	À vérifier	À vérifier	China	À vérifier
Partial Cardiac DenervationPostoperative atrial fibrillation (POAF) is the most common arrhythmia following cardiac surgery and is associated with increased risks of mortality, stroke, myocardial infarction, and hospital readmission. The cardiac autonomic nervous system plays an important role in the development of POAF and may represent a potential target for preventive intervention. The CALM trial is a multicenter, randomized controlled trial designed to evaluate the efficacy and safety of partial cardiac denervation for the prevention of POAF in patients undergoing isolated coronary artery bypass grafting (CABG). A total of approximately 1,470 participants will be randomly assigned in a 1:1 ratio to undergo CABG with partial cardiac denervation or CABG alone. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad. The trial will evaluate the incidence of POAF within the first 6 postoperative days and the occurrence of long-term adverse clinical events. Participants will undergo scheduled rhythm monitoring and clinical follow-up, and all participants will be followed until the last enrolled participant completes 3 years of follow-up after surgery.	Maladie coronarienne	Non applicable	À vérifier	China	À vérifier

Essais cliniques

5

Molécule	Indication / population	Phase	NCT	Titre	Statut
Partial Cardiac Denervation	Maladie coronarienne	Non applicable	NCT07918781	CALM — Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG	NOT_YET_RECRUITING
OCR-Prompt-LLM Information Extraction and Classification Workflow (OCR-Prompt-LLM)	Maladie coronarienne	À vérifier	NCT07449429	OCR-LLM-CHD — AI-Assisted Coronary Syndrome Subtyping From Admission History of Present Illness: A Clinician Reader Study	COMPLETED
Norepinephrine	Maladie coronarienne	Non applicable	NCT07667829	Vasopressor Agents in Pulmonary Hypertension Crisis	RECRUITING
Norepinephrine	Maladie coronarienne	Non applicable	NCT07562932	ACTION-CS — Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock	RECRUITING
IVUS-Guided Sirolimus-Coated Balloon	Maladie coronarienne	Non applicable	NCT07796412	IVUS-SCB — IVUS-Guided Sirolimus-Coated Balloon Versus Sirolimus-Eluting Stent for De Novo Large Vessel Lesions in ACS	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.